FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average	burden								
hours per response	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name at GOLD (Last)	3. E	Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS,      INC. [ REGN ]      Date of Earliest Transaction (Month/Day/Year)     09/10/2021									ationship of Reporting c all applicable) Director Officer (give title below)		ng Pers	son(s) to Iss 10% Ov Other (s below)	wner				
(Street)	ΓOWN N	State)	10591 (Zip)		4. 1	f Ame	endme		·	Driginal Filed (Month/Day/Year)					vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
1. Title of Security (Instr. 3)  2. Trans Date					2. Transaction 2. Date E (Month/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa	3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amou Securiti Benefic Owned	int of es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) o (D)	Price	•	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common Stock				09/10	09/10/2021				M <sup>(1)</sup>		2,479	) A	\$38	0.95	8,	8,370		D	
Common Stock			09/10	0/2021				S <sup>(1)</sup>		2,479	D	\$6	\$650		5,891		D		
		٦	able II -								osed of converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deen Executio if any (Month/D	n Date,	4. Transaction Code (Instr. 8)		n of E		Expiration	6. Date Exercisi Expiration Date (Month/Day/Yea		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		De Se (Ir	B. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares	er					
Non- Qualified Stock Option (right to	\$380.95	09/10/2021			<b>M</b> <sup>(1)</sup>			2,479	(2)	Į (	01/02/2028	Common Stock	2,47	9	\$0.0	0		D	

## **Explanation of Responses:**

- 1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- 2. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

/s/\*\*Joseph L. Goldstein

09/13/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.